Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA
Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA )
6 May 2016

First outcome results from MINDACT breast cancer clinical trial

Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium
First outcome results from MINDACT breast cancer clinical trial ( Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium )
6 May 2016

Genetics may influence risk for breast cancer after chest radiotherapy to treat childhood cancer

Dr Lindsay Morton - National Cancer Institute, Bethesda, USA
Genetics may influence risk for breast cancer after chest radiotherapy to treat childhood cancer ( Dr Lindsay Morton - National Cancer Institute, Bethesda, USA )
6 May 2016

A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer

Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA
A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )
6 May 2016

5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
6 May 2016

CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses

Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )
6 May 2016

New investigational targeted therapeutic, entrectinib, shows early promise

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA
New investigational targeted therapeutic, entrectinib, shows early promise ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA )
5 May 2016

Paediatric and adult high grade gliomas: A tale of a histone tail

Dr Nada Jabado - McGill University, Montreal, Canada
Paediatric and adult high grade gliomas: A tale of a histone tail ( Dr Nada Jabado - McGill University, Montreal, Canada )
5 May 2016

Galectins in tumour immunity

Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina
Galectins in tumour immunity ( Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina )
5 May 2016

Treatment of relapsed myeloma with novel targeted and immune therapies

Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA
Treatment of relapsed myeloma with novel targeted and immune therapies ( Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA )
5 May 2016

Targeting T regs in tumours

Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA
Targeting T regs in tumours ( Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA )
5 May 2016

Multiplex IHC as biomarkers for cancer immunotherapy

Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA
Multiplex IHC as biomarkers for cancer immunotherapy ( Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA )
5 May 2016